Caribou Biosciences to Present at Upcoming Investor Conferences
March 07 2022 - 4:10PM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, announced today
that Rachel Haurwitz, Ph.D., Caribou’s president and chief
executive officer, will present a company overview at the following
upcoming investor conferences in March:
- Oppenheimer
32nd Annual Healthcare
ConferenceWednesday, March 16th, at 10:00 am ET
- H.C. Wainwright Gene
Therapy and Gene Editing ConferenceWednesday, March 30th,
with a corporate overview presentation webcast available beginning
at 7:00 am ET
Webcasts of the presentations will be accessible via Caribou’s
website on the Events page. Archived copies of the webcasts will be
available on the Caribou website for 30 days after the events.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Type II and Type V CRISPR systems: the
nuclease protein that cuts DNA and the RNA molecule(s) that guide
the nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems
occasionally edit unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
chRDNAs (pronounced “chardonnays”), RNA-DNA hybrid guides that
direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences,
Inc.Caribou Biosciences is a clinical-stage CRISPR
genome-editing biopharmaceutical company dedicated to developing
transformative therapies for patients with devastating diseases.
The company’s genome-editing platform, including its proprietary
Cas12a chRDNA technology, enables superior precision to develop
cell therapies that are specifically engineered for enhanced
persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T
and CAR-NK cell therapies for the treatment of patients with
hematologic malignancies and solid tumors. Follow us @CaribouBio
and visit www.cariboubio.com.
“Caribou Biosciences” and the Caribou logo are
registered trademarks of Caribou Biosciences, Inc.
Caribou Biosciences,
Inc. Contacts: |
Amy Figueroa, CFA |
Investor Relations and Corporate
Communications |
afigueroa@cariboubio.com |
|
Investors: |
Elizabeth Wolffe, Ph.D., and
Sylvia Wheeler |
Wheelhouse LSA |
lwolffe@wheelhouselsa.com |
swheeler@wheelhouselsa.com |
|
Media: |
Greg Kelley |
Ogilvy |
gregory.kelley@ogilvy.com |
617-461-4023 |
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024